Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in Hormone-naïve Prostate Cancer with Bone Metastasis
NCT00237146Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2003
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in prostate cancer (PCa), sponsored by Novartis. Primary endpoints: Quality of Life and Incidence of Skeletal-related Events. Started Nov 2003; status: completed.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00237146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237146.